Rosetta Genomics Ltd. Announces Expansion of its Research Facility; Expects to Add 70 Employees

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, July 17 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd , a leading microRNA company, announced today the expansion of its Israeli research facility. The company is adding the new laboratories to its state-of-the-art facilities in order to meet its research and development needs for its microRNA-based diagnostic programs. The company expects to grow to approximately 70 employees by the end of the year.

"This expansion will enable us to advance new development programs, and accommodate the large number of scientists that have joined Rosetta recently and those we expect to add in the future," said Amir Avniel, Rosetta Genomics' Chief Executive Officer. "Our proprietary discovery platform is capable of utilizing over twelve thousand predicted and validated microRNAs, including over 1000 proprietary microRNAs, which are expressed in different tissues. This platform provides us with the foundation upon which we can advance microRNA-based diagnostic products in key oncology indications. The new lab space is essential for the success of these efforts."

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring (endogenous), molecule that initiates the RNAi process. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human illnesses. In addition, microRNAs have been shown to have different expression levels in certain pathological versus normal tissues. As a result, these differences may provide the basis for a novel diagnostic strategy for a wide range of diseases.

About Rosetta Genomics

Rosetta Genomics is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases. For more information please visit: www.rosettagenomics.com

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of miRNAs in human physiology and disease, the potential of microRNAs in the development of therapeutics and diagnostic products, the expansion of Rosetta's laboratory facilities and the expectation to add an additional 20 scientists to its research team by the end of the year, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of Rosetta's product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; Rosetta's short operating history; and Rosetta's ability to successfully hire additional scientists and staff; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media Alan Zachary T: +1-(312)-944-6784 media@rosettagenomics.com Investors Juliane Snowden T: +1-(212)-213-0006 investors@rosettagenomics.com

Rosetta Genomics Ltd

CONTACT: Contact: Media, Alan Zachary, T: +1-(312)-944-6784,media@rosettagenomics.com; Investors, Juliane Snowden, T:+1-(212)-213-0006, investors@rosettagenomics.com

Back to news